Anti-Candida and anti-Cryptococcus evaluation of 15 non-alkaloidal compounds from Pterogyne nitens

详细信息    查看全文

• 作者：Caroline Sprengel Lima¹ ; Carlos Roberto Polaquini¹ ; Mariana Bastos dos Santos¹ ; Fernanda Patrí ; cia Gullo² ; Fernanda Sangalli Leite² ; Liliane Scorzoni² ; Vanderlan da Silva Bolzani³ ; Maria José ; Soares Mendes-Giannini² ; Ana Marisa Fusco-Almeida² ; André ; ia Alves Rezende⁴ ; Luis Octavio Regasini¹ ; ^{regasini@ibilce.unesp.br" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Candida ; Cryptococcus ; Antifungal ; Pterogyne nitens ; Flavonoid ; Opportunistic fungi
• 刊名：Asian Pacific Journal of Tropical Biomedicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：6
• 期：10
• 页码：841-845
• 全文大小：395 K

文摘

To evaluate anti-Candida and anti-Cryptococcus activities of 15 non-alkaloidal compounds from Pterogyne nitens Tulasne (Leguminosae), a South American medicinal plant.

Methods

Compounds were submitted to antifungal assays, using microdilution method described by Clinical and Laboratory Standards Institute document, with minor modifications. Five species of Candida and two species of Cryptococcus, including clinical isolates were screened. Antifungal activity was expressed by minimum inhibitory concentration (MIC). Amphotericin B and fluconazole were used as standard antifungal drugs.

Results

Among tested compounds, six substances presented fungal growth inhibition (MIC < 31.2 μg/mL) [three flavone derivatives (1&ndash;3), a glycosylated flavonol derivative (5) and two phenolic acids (10 and 12)]. Sorbifolin (1), exhibited potent antifungal activity, demonstrating MIC value of 3.90 μg/mL against Candida glabrata ATCC 90030, Cryptococcus gattii 118 and fluconazole-resistant clinical isolate of Cryptococcus neoformans var. grubii. Pedalin (2) and nitensoside B (3), two glycosylated flavone derivatives, were active against Cryptococcus neoformans ATCC 90012 (MIC = 7.80 μg/mL).

Conclusions

Flavone derivatives from Pterogyne nitens can serve as prototypes for the design and development of innovative anti-Candida and anti-Cryptococcus hits.